Search Results - "Doyle, Ralph T."

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia by Bhatt, Deepak L, Steg, P. Gabriel, Miller, Michael, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Doyle, Ralph T, Juliano, Rebecca A, Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Ballantyne, Christie M

“…In this multicenter, placebo-controlled trial involving statin-treated patients with hypertriglyceridemia, the risk of ischemic events, including…”
Get full text

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT by Bhatt, Deepak L, Steg, Ph Gabriel, Miller, Michael, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Doyle, Jr, Ralph T, Juliano, Rebecca A, Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Gregson, John, Pocock, Stuart J, Ballantyne, Christie M

“…In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, among patients with…”
Get full text

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States by Bhatt, Deepak L., Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Steg, Ph Gabriel, Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Olshansky, Brian, Chung, Mina K., Gibson, C. Michael, Giugliano, Robert P., Budoff, Matthew J., Ballantyne, Christie M.

“…BACKGROUND:Some trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified…”
Get full text

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI by Peterson, Benjamin E, Bhatt, Deepak L, Steg, Ph Gabriel, Miller, Michael, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Juliano, Rebecca A, Jiao, Lixia, Doyle, Jr, Ralph T, Granowitz, Craig, Gibson, C Michael, Pinto, Duane, Giugliano, Robert P, Budoff, Matthew J, Tardif, Jean-Claude, Verma, Subodh, Ballantyne, Christie M

“…Background Patients who undergo percutaneous coronary intervention (PCI) are at increased risk for recurrent cardiovascular events despite aggressive medical…”
Get full text

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study) by Miller, Michael, Ballantyne, Christie M., Bays, Harold E., Granowitz, Craig, Doyle, Ralph T., Juliano, Rebecca A., Philip, Sephy

“…Icosapent ethyl is pure prescription eicosapentaenoic acid approved at 4 g/day as an adjunct to diet to reduce triglycerides (TG) in adults with TG ≥500 mg/dl…”
Get full text

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT by Olshansky, Brian, Bhatt, Deepak L, Miller, Michael, Steg, Ph Gabriel, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Doyle, Jr, Ralph T, Juliano, Rebecca A, Jiao, Lixia, Kowey, Peter R, Reiffel, James A, Tardif, Jean-Claude, Ballantyne, Christie M, Chung, Mina K

“…Background In REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial), icosapent ethyl (IPE) versus placebo) reduced…”
Get full text

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial by Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.

“…Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have…”
Get full text

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction by Gaba, Prakriti, Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Tardif, Jean-Claude, Giugliano, Robert P., Martens, Fabrice M.A.C., Gibson, C. Michael, Ballantyne, Christie M.

“…REDUCE-IT was a double-blind trial that randomized 8,179 statin-treated patients with controlled low-density lipoprotein cholesterol and moderately elevated…”
Get full text

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL by Majithia, Arjun, Bhatt, Deepak L., Friedman, Allon N., Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Budoff, Matthew, Preston Mason, R., Tardif, Jean-Claude, Boden, William E., Ballantyne, Christie M.

“…Chronic kidney disease is associated with adverse outcomes among patients with established cardiovascular disease (CVD) or diabetes. Commonly used medications…”
Get full text

Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies by Olshansky, Brian, Chung, Mina K, Budoff, Matthew J, Philip, Sephy, Jiao, Lixia, Doyle, Jr, Ralph T, Copland, Christina, Giaquinto, Alex, Juliano, Rebecca A, Bhatt, Deepak L

“…Abstract Mineral oil is often used as a clinical trial placebo. Pharmaceutical-grade mineral oil consists of a mixture of saturated hydrocarbons, with a purity…”
Get full text

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses by Peterson, Benjamin E., Bhatt, Deepak L., Steg, Ph Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Gibson, C. Michael, Pinto, Duane, Giugliano, Robert P., Budoff, Matthew J., Tardif, Jean-Claude, Verma, Subodh, Ballantyne, Christie M.

“…Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. REDUCE-IT (The…”
Get full text

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial by Sayah, Neila, Bhatt, Deepak L, Miller, Michael, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Jiao, Lixia, Pineda, Armando Lira, Doyle, Jr, Ralph T, Tardif, Jean Claude, Ballantyne, Christie M, Steg, Ph Gabriel

Get full text

Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study by Davidson, Michael H., MD, Stein, Evan A., MD, PhD, Bays, Harold E., MD, Maki, Kevin C., PhD, Doyle, Ralph T, Shalwitz, Robert A., MD, Ballantyne, Christie M., MD, Ginsberg, Henry N., MD

“…Abstract Background: Patients with elevated serum triglyceride (TG) levels often have elevations in non-high-density lipoprotein cholesterol (non-HDL-C) levels…”
Get full text

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl by Szarek, Michael, Bhatt, Deepak L., Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Tardif, Jean-Claude, Ballantyne, Christie M., Mason, R. Preston, Ketchum, Steven B., Lira Pineda, Armando, Doyle, Ralph T., Steg, Ph. Gabriel

“…Elevated lipoprotein(a) (Lp[a]) concentrations are associated with increased cardiovascular event risk even in the presence of well-controlled low-density…”
Get full text

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT by Gaba, Prakriti, Bhatt, Deepak L., Giugliano, Robert P., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Tardif, Jean-Claude, Ballantyne, Christie M., Pinto, Duane S., Budoff, Matthew J., Gibson, C. Michael

“…REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) randomized statin-treated patients with elevated triglycerides to…”
Get full text

Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials) by Mosca, Lori, MD, MPH, PhD, Ballantyne, Christie M., MD, Bays, Harold E., MD, Guyton, John R., MD, Philip, Sephy, RPh, PharmD, Doyle, Ralph T., BA, Juliano, Rebecca A., PhD

“…There are limited data on the efficacy and safety of triglyceride (TG)-lowering agents in women. We conducted subgroup analyses of the effects of icosapent…”
Get full text

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn by Miller, Michael, Bhatt, Deepak L, Brinton, Eliot A, Jacobson, Terry A, Steg, Philippe Gabriel, Pineda, Armando Lira, Ketchum, Steven B, Doyle, Jr, Ralph T, Tardif, Jean-Claude, Ballantyne, Christie M

“…Metabolic syndrome (MetSyn) is associated with high risk of cardiovascular (CV) events, irrespective of statin therapy. In the overall REDUCE-IT study of…”
Get full text

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results by Olshansky, Brian, Bhatt, Deepak L, Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Doyle Jr, Ralph T, Juliano, Rebecca A, Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Mehta, Cyrus, Mukherjee, Rajat, Ballantyne, Christie M, Chung, Mina K

Get full text

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies by Ballantyne, Christie M, Bays, Harold E, Philip, Sephy, Doyle, Ralph T, Braeckman, Rene A, Stirtan, William G, Soni, Paresh N, Juliano, Rebecca A

“…Abstract Background and aims Remnant-like particle cholesterol (RLP-C) is atherogenic and may increase atherosclerotic cardiovascular disease risk. Icosapent…”
Get full text

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies by Ballantyne, Christie M., MD, Bays, Harold E., MD, Braeckman, Rene A., PhD, Philip, Sephy, RPh, PharmD, Stirtan, William G., PhD, Doyle, Ralph T., BA, Soni, Paresh N., MD, PhD, Juliano, Rebecca A., PhD

“…Background Apolipoprotein C-III (ApoC-III) regulates lipoprotein and triglyceride (TG) metabolism and may have a causal role in cardiovascular disease. In the…”
Get full text